Frontier Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Frontier Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-827	Closed	-$7.05M	–	378
2015 Q1	$7.05M	Sell	827 -40	-5%	-$350K	0.05%	283
2014 Q4	$7.62M	Buy	+867	New	+$5.03M	0.06%	275

Other funds holding EIGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Frontier Capital Management's EIGR Position: Q2 2015 in Review

Frontier Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 827 shares — an estimated $7.05M sold.

Frontier Capital Management first reported a position in EIGR in Q4 2014 and held it in 2 quarters. The position peaked at $7.62M in Q4 2014. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

Frontier Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Frontier Capital Management sold 827 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $7.05M.
Frontier Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Frontier Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $7.62M in Q4 2014.
44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Frontier Capital Management's 13F filing for Q2 2015, filed 24 Jul 2015.